Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed's Products and the Importance of Early Detection

BERKELEY, US and MAINZ, Germany – September 18, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer.

"We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the intention to launch a pivotal PMA trial by the end of 2025," commented Guido Baechler, Chief Executive Officer of Mainz Biomed.

Petra Smeltzer Starke commented, "I am proud and excited to work with Mainz Biomed as they push the envelope on the early detection of colorectal cancer and importantly the detection of pre-cancerous polyps."

Please visit Mainz Biomed's official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Petra Smeltzer Starke

Petra Smeltzer Starke's phenomenal career started from studying international business, trade, and diplomacy at the Prague School of Economics while supporting herself as a model. Petra's passion for Fashion translates into her modeling successes notwithstanding, Starke finished both undergraduate and graduate degrees at the top of her class and moved to the United States to attend law school at Georgetown University.

Starke was first in her class in law school & practiced law at the international law firm of O'Melveny & Myers, LLP representing many political nominees and appointees during the Bush Administration. Starke was subsequently recruited for the Obama Presidential Transition and later the Obama White House where she served as General Counsel to the White House Council of Economic Advisors and Senior Advisor to the President. Starke has Counseled American Presidents, and global Diplomatic Leaders around the world, and established a phenomenal international network. Starke's expertise helped the Biden-Harris Transition Team – ethics and avoiding conflicts of interest.

About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries

MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.